Drugs / GPA-TriMAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03649529 | Sep 2018 → Sep 2021 | melanoma | Timmune Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPA-TriMAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03649529 ↗ |
| Action | Deplete | “When infused back to the patient, the GPA-TriMAR-T cells will recognize and kill target cells that express gp100(209-217) peptides in the form MHC-I complex, thus eliminating...” NCT03649529 ↗ |
| Modality | Cell therapy | “Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells.” NCT03649529 ↗ |